Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC). 18F-PSMA-1007 PET/CT for response assessment in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback